Selective killing of human monocytes and cytokine release provoked by sphingomyelinase (beta-toxin) of Staphylococcus aureus.
The best-known activity of Staphylococcus aureus sphingomyelinase C, alias beta-toxin, is as a hemolysin that provokes hot-cold lysis of erythrocytes which contain substantial amounts of sphingomyelin in the plasma membrane. Sheep erythrocytes are most susceptible, and we found that one hemolytic unit, representing the toxin concentration that elicits 50% hemolysis of 2.5 X 10(8) erythrocytes per ml, corresponds to 0.05 enzyme units or to approximately 0.25 microg of sphingomyelinase per ml. The cytotoxic action of beta-toxin on nucleated cells has not been described in any detail before, and the present investigation was undertaken to fill this information gap. We now identify beta-toxin as a remarkably potent monocytocidal agent. At a concentration of 0.001 U/ml, corresponding to approximately 5 ng/ml, beta-toxin killed over 50% of human monocytes (10(6) cells per ml) within 60 min. By contrast, 1 to 5 microg of beta-toxin per ml had no cytocidal effects on human granulocytes, fibroblasts, lymphocytes, or erythrocytes. A selective monocytocidal action was also observed with sphingomyelinase C from Bacillus cereus and a Streptomyces sp., whereas phospholipase A2 and phospholipase D at 100 U/ml were without effect. Monocytes succumbing to the action of beta-toxin processed and released interleukin-1beta, soluble interleukin-6 receptor, and soluble CD14 into the supernatant. Thus, monocyte killing by beta-toxin is associated with cytokine-related events that are important for the initiation and progression of infectious disease. These findings uncover a potentially important role for sphingomyelinase as a determinant of microbial pathogenicity.
Walev
I
I
Institute of Medical Microbiology and Hygiene, University of Mainz, Germany.
Weller
U
U
Strauch
S
S
Foster
T
T
Bhakdi
S
S
D015703:Antigens, CD / Q000378:metabolism; D001427:Bacterial Toxins / Q000494:pharmacology*; D016923:Cell Death; D016207:Cytokines / Q000378:metabolism*; D003603:Cytotoxins / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005098:Exotoxins / Q000494:pharmacology*; D006460:Hemolysin Proteins; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism; D018950:Lipopolysaccharide Receptors / Q000378:metabolism; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D018123:Receptors, Interleukin / Q000378:metabolism; D019947:Receptors, Interleukin-6; D013108:Sphingomyelin Phosphodiesterase / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000201:enzymology; D013997:Time Factors
D015703:Antigens, CD; D001427:Bacterial Toxins; D016207:Cytokines; D003603:Cytotoxins; D005098:Exotoxins; D006460:Hemolysin Proteins; D007375:Interleukin-1; D018950:Lipopolysaccharide Receptors; D018123:Receptors, Interleukin; D019947:Receptors, Interleukin-6; D013108:Sphingomyelin Phosphodiesterase; C029878:hlb protein, Staphylococcus aureus